ProCE Banner Activity

CE

State-of-the-Art Care in CLL/SLL: Best Practices in an Expanding Therapeutic Landscape

Video

Watch this on-demand webcast from a live meeting series to hear guidance from clinical pharmacy specialists on management of patients with CLL/SLL, including current clinical decisions for selecting therapy, understanding adverse events and toxicity management, and pharmacist considerations for treatment.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 07, 2023

Expiration: March 06, 2024

No longer available for credit.

Share

Faculty

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Caitlin R. Rausch

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Genentech, a member of the Roche Group

Target Audience

The target audience is pharmacists, including clinical and health-system, ambulatory care, and community pharmacists, who care for patients with CLL/SLL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in health-system pharmacy.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of pharmacists in the management of patients with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current evidence and guidelines for the treatment and management of treatment-naive and relapsed/refractory CLL/SLL, taking into consideration the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference

  • Foster collaborative discussions between patients, caregivers, and healthcare professionals to guide personalized treatment planning

  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles among agents used to treat CLL/SLL

  • Evaluate strategies to proactively mitigate and manage treatment-related adverse events that occur with current and emerging approaches

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Victoria Nachar, PharmD, BCOP: consultant/advisor/speaker: ADC Therapeutics, Genmab

Caitlin R. Rausch, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-002-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.